IO Biotech, Inc. (IOBTQ) Financials
Annual revenue, profitability and per-share results for IO Biotech, Inc., as reported in SEC filings.
Revenue • FY2024
$0
Net income • FY2024
-$95.49M
▼ 10.9%YoY
Diluted EPS • FY2024
-$1.45
▲ 26.8%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2024 | $0 | -$95.49M | — | -$1.45 | -$82.39M | — | — |
| FY2023 | $0 | -$86.08M | — | -$1.98 | -$72.06M | — | — |
| FY2022 | $0 | -$71.46M | — | -$2.48 | -$60.42M | — | — |
| FY2021 | $0 | -$67.88M | — | -$17.30 | -$40.8M | — | — |
Figures as reported in IO Biotech, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a IOBTQ filing.
Get an email when IOBTQ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.